GE Healthcare
To see an up-to date selection of historical analyses and insights on
GE Healthcare,
visit our
new, dynamically updated Company Summary report pages for GE Healthcare.
As a Guest User, you will have FREE access to a selection of historical analyses
and insights from EvaluatePharma®.
How to access FREE content
- Search the content using the search box at the top of every page
- Browse content by Company, Product, Generic Name, Therapeutic Category or Indication using the "Browse By" link from the navigation bar
- Create Peer Groups to compare Companies using the "Peer Groups" link from the navigation bar
Register for FREE to access even more content including 2007
Product Sales and Rankings.
A small selected sample of reports and related news headlines for
GE Healthcare are available below.
Free sample reports are also available for other Companies.
To find out how you can access more detailed information on
GE Healthcare,
or on any other Company covered by EvaluatePharma® Contact Us today.
CONSENSUS FORECASTS ($US mln) - Sales Forecasts available to EvaluatePharma Subscribers
|
|
|
Annual Sales WW - Sales |
Growth per Year (%) |
|
|
Rank |
Product |
Generic Name |
Pharmacological Class |
2006 |
2007 |
2007 |
| GE Healthcare |
1 |
Visipaque |
iodixanol |
X Ray contrast media |
427 |
443 |
|
4% |
|
|
|
2 |
Omnipaque |
iohexol |
X Ray contrast media |
400 |
416 |
|
4% |
|
|
|
3 |
Myoview |
technetium Tc-99m tetrofosmin |
Radiodiagnostic agent |
321 |
331 |
|
3% |
|
|
|
|
|
Note: Shaded Cells |
|
|
|
|
PIPELINE ANALYSIS - Sales Forecasts available to EvaluatePharma Subscribers
|
|
|
|
|
Rank |
Product |
Therapeutic Category |
Therapeutic Subcategory |
Pharmacological Class |
Phase (Current) |
| GE Healthcare |
- |
NC100668 |
Various |
Diagnostic imaging |
Nuclear imaging agent |
Phase II |
|
|
- |
Pittsburgh Compound B (PIB) |
Various |
Diagnostic imaging |
PET imaging agent |
Phase I |
|
|
- |
NC100697 |
Various |
Diagnostic imaging |
Diagnostic imaging agent |
Pre-clinical |
|
|
|
FINANCIAL DATA ($US mln) - Forecasts available to EvaluatePharma Subscribers
|
| GE Healthcare |
|
|
2005 |
2006 |
| Valuation Measures |
| Based on Latest Share Prices |
| Valuing the Equity |
|
|
| Valuing the Enterprise |
|
|
| Forecast Financials |
| Income Statement |
| Total Revenues |
0 |
0 |
| Other Income/ Expense - Net |
0 |
0 |
| Tax |
0 |
0 |
| Net Income - Reported |
0 |
0 |
| Net Income - Normalised |
0 |
0 |
|
|
| Per Share Data |
| DPS |
0.00 |
0.00 |
|
|
|
NEWS - Selected Product News Headlines (as of 11 June 2008)
|
| Acusphere Announces Results of FDA Advisory Committee Meeting
|
(Acusphere)
|
10-Dec-2008 |
| Therapeutic focus – diagnostic agents gaining clarity
|
(Molecular Insight Pharmaceuticals)
|
08-Dec-2008 |
| Acusphere, Inc. Announces Posting of Briefing Documents for FDA Cardio Renal Drugs Advisory Committee Meeting on Imagify(TM)
|
(Acusphere)
|
08-Dec-2008 |
| GE Healthcare Unveils Signa Magnetic Resonance Imaging Oncology Package at Astro
|
(GE Healthcare)
|
21-Sep-2008 |
| FDA Approves GE Healthcares Adreview (Lobenguane I 123 Injection) Diagnostic Agent for Detecting Neuroendocrine Tumors in Children, Adults
|
(GE Healthcare)
|
19-Sep-2008 |
| Phase III Study Results Demonstrate That Hexvix Cystoscopy Leads to Significantly Improved Patient Outcome
|
(Photocure)
|
12-Sep-2008 |
| GE Healthcare Introduces Ultrasound Fusion
|
(GE Healthcare)
|
02-Sep-2008 |
| GE Healthcare Recognizes First Magnetic Resonance Imaging System to Receive Ecomagination Certification
|
(GE Healthcare)
|
11-Aug-2008 |
| Healthcare Introduces Newest Technology in Preclinical Computed Tomography Imaging
|
(GE Healthcare)
|
04-Aug-2008 |
| GE Healthcare Announces Phase I Results With Amyloid Imaging Agent GE-067
|
(GE Healthcare)
|
29-Jul-2008 |
| U.S. FDA Clears Ge Healthcare's New Additions to Pet/ct Line, Extending Ge’s Leadership in Cancer Detection, Management and Research
|
(GE Healthcare)
|
24-Jul-2008 |
| Published Study Demonstrates Lower Serum Creatinine Levels After Contrast Media Administration With Iodixanol Than With Iopromide
|
(GE Healthcare)
|
16-Jul-2008 |
| GE Healthcares Application for Adreview (Lobenguane I 123 Injection) Accepted by the FDA for Priority Review
|
(GE Healthcare)
|
12-Jun-2008 |
| GE Healthcare Announces Updates to Optison Prescribing Information
|
(GE Healthcare)
|
10-Jun-2008 |
| GE Healthcare Announces World’s First High Definition CT Scanner
|
(GE Healthcare)
|
03-Jun-2008 |
| FDA Gives Green Light to GE Healthcare Surgery; Shipping Resumes
|
(GE Healthcare)
|
03-Jun-2008 |
| GE Healthcare Introduces New 3.0T MR Scanner
|
(GE Healthcare)
|
05-May-2008 |
| GE's Transformation of Cardiovascular Ultrasound Continues at ACC
|
(GE Healthcare)
|
30-Mar-2008 |
| GE Healthcare Introduces Enhancements to Leading Maternal/fetal Monitor Series
|
(GE Healthcare)
|
26-Mar-2008 |
| GE Healthcare Launches Diagnostic Advancements on Premier Women’s Health Ultrasound System at AIUM 2008
|
(GE Healthcare)
|
12-Mar-2008 |
|
|
|
IN-DEPTH COMPETITIVE INTELLIGENCE AVAILABLE ON
|
|
|
|
|
Product |
Generic Name |
| GE Healthcare |
5T4 Imaging MAb |
- |
|
|
Abdoscan |
ferristene |
|
|
AcuTect |
technetium Tc-99m apcitide |
|
|
Adreview |
lobenguane I-123 |
|
|
Alzheimer's Diagnostic Research Project |
- |
|
|
Alzheimer's Research Project |
- |
|
|
Alzheimer's Therapy Research Project |
- |
|
|
Cancer diagnostics |
- |
|
|
Ceretec |
technetium Tc-99m exametazime |
|
|
DaTSCAN |
ioflupane |
|
|
Disease Diagnosis Research Project |
- |
|
|
DSMA Kidney Reagent |
technetium Tc-99m succimer |
|
|
EchoSeed |
iodine-125 |
|
|
FDG |
fluordeoxyglucose fl-18 |
|
|
FLT |
fluorothymidine fl-18 |
|
|
HeliSpin |
- |
|
|
Hexvix |
hexaminolevulinate |
|
|
Hypaque |
diatrizoate |
|
|
Imagify |
perflubutane |
|
|
Indium DTPA In-111 |
indium In-111 pentetate disodium |
|
|
Indium-Oxine |
indium In-111 oxyquinoline |
|
|
LeukoScan |
sulesomab |
|
|
Metastron |
strontium-89 |
|
|
Myoview |
technetium Tc-99m tetrofosmin |
|
|
NC100668 |
- |
|
|
NC100692 |
- |
|
|
NC100697 |
tropantiol |
|
|
Neotect/NeoSpect |
technetium Tc-99m depreotide |
|
|
Nephroflow |
iodohippurate I-123 |
|
|
Non-nuclear Contrast Media |
- |
|
|
Omnipaque |
iohexol |
|
|
Omniscan |
gadodiamide |
|
|
OncoSeeds |
iodine-125 |
|
|
Optison |
octafluoropropane |
|
|
Peptide PET Imaging Agent |
- |
|
|
Pittsburgh Compound B (PIB) |
- |
|
|
Sestamibi |
technetium Tc-99m sestamibi |
|
|
Sonazoid |
perflubutane |
|
|
SPECTamine |
iofetamine I-123 |
|
|
Teslascan |
mangafodipir |
|
|
TheraSeed |
palladium-103 brachytherapy |
|
|
Tositumomab |
iodine I 131 tositumomab |
|
|
Visipaque |
iodixanol |
|
|
|
EvaluatePharma® provides historic and forecast sales from 1986 to 2012 for worldwide and US Rx
(prescription drugs) and OTC drugs. EvaluatePharma® analysts continuously update company models from SEC filings,
annual reports, investor/analyst presentations, company press releases, FDA and USPTO. Consensus forecasts
for marketed and emerging products are built-up using recent research reports from top equity analysts.
Analyse pharma and biotech products by market status or development phase (e.g., preclinical, phase I,
phase II, phase III, filed, approved, withdrawn, disposed etc), therapeutic category, product sourcing strategy,
patent expiry and patent life remaining, originator, technology, indication, pharmacological class, deal dates,
deal types and partners, launch dates, FDA approval data and new molecular entity (NME) age -
plus many more data items and analytics unique to EvaluatePharma®.
Aggregations of these measures at a high-level means that companies may be ranked against each other on items
such as: market capitalization, patent risk, R&D spend, freshness index, sales strategy (inlicensed vs
organic sales), sales by therapy area or technology and various other concentration measures. These
aggregations make EvaluatePharma® ideal for competitive benchmarking, ranking and Peer Group analysis.
Note: When a merger or acquisition is agreed, a virtual merged Company will be added to the list of available
Company reports. Any information presented for a virtual merged company is for illustrative purposes, only.
